Kodiak Sciences Inc., a cutting-edge biopharmaceutical company, is focused on researching, developing, and distributing therapeutics for the treatment of retinal diseases. The Palo Alto-based firm boasts a formidable pipeline, with its lead product candidate, tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer, currently in Phase IIb/III clinical trials to tackle wet age-related macular degeneration (AMD) and in Phase III clinical trials for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. Additionally, the company's preclinical stage product candidates include KSI-501, a bispecific conjugate that aims to treat retinal diseases with an inflammatory component, and KSI-601, a triplet biopolymer conjugate designed to treat dry AMD. Previously known as Oligasis, LLC, the company switched to its current name in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is a leader in the biopharmaceutical space.
Kodiak Sciences Inc's ticker is KOD
The company's shares trade on the LSE stock exchange
They are based in London, England
There are 1-10 employees working at Kodiak Sciences Inc
It is https://kodiak.com/
Kodiak Sciences Inc is in the Basic Materials sector